Table 1:
Baseline Characteristics
| All (n=29) | mPAP/CO slope >3 | |||
|---|---|---|---|---|
| No (n=8) | Yes (n=21) | p | ||
| Age at time catheterization, years | 29±6 | 27±4 | 30±5 | 0.09 |
| Age at Fontan operation, years | 5±3 | 4±1 | 5±3 | 0.3 |
| Male | 16 (55%) | 4 (50%) | 12 (57%) | 0.7 |
| Body surface area, m2 | 1.9±0.3 | 1.8±0.2 | 1.9±0.3 | 0.6 |
| Left ventricle | 18 (62%) | 4 (50%) | 14 (67%) | 0.7 |
| Atriopulmonary Fontan | 9 (31%) | 2 (25%) | 7 (33%) | 0.2 |
| History of atrial arrhythmia | 13 (45%) | 3 (38%) | 10 (48%) | 0.2 |
| Cirrhosis | 11 (38%) | 2 (25%) | 9 (42%) | 0.4 |
| Laboratory tests | ||||
| Hemoglobin, g/dl | 14.3 ±2.5 | 13.9±1.8 | 14.9±2.1 | 0.3 |
| Platelet, x109/l | 139±41 | 145±22 | 128±33 | 0.2 |
| Albumin, g/dl | 4.3±0.7 | 4.2±0.4 | 4.3±0.6 | 0.8 |
| Aspartate aminotransferase, U/l | 39±6 | 41±5 | 38±7 | 0.6 |
| Alanine aminotransferase, U/l | 47±8 | 46±4 | 47±8 | 0.7 |
| Therapies | ||||
| Paced rhythm | 3 (10%) | 1 (13%) | 2 (10%) | 0.4 |
| BB or CCB therapy | 6 (21%) | 1 (13%) | 5 (24%) | 0.5 |
| RAAS antagonist | 9 (31%) | 2 (26%) | 7 (33%) | 0.2 |
| Warfarin | 10 (34%) | 2 (26%) | 8 (38%) | 0.3 |
| Diuretics | 12 (41%) | 2 (25%) | 10 (48%) | 0.06 |
MRE: magnetic resonance elastography; GFR: glomerular filtration rate; NT proBNP: N-terminal pro hormone brain natriuretic peptide; VO2: oxygen consumption; FEV1: forced expiratory volume; FVC: forced vital capacity; BB: Beta-blocker; CCB: calcium channel blockers; RAAS: renin angiotensin aldosterone system; mPAP/CO slope: slope of mean pulmonary artery pressure versus cardiac output